Moreover, ublituximab recently showed promising efficacy when combined with the Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib in a phase II study of relapsed/refractory CLL patients, with ~90% of patients responding, and two complete responses (24). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.